ClinicalTrials.gg
CompletedNCT04218513Updated Mar 22, 2021

Drug-drug Interaction Study Between Edaravone and 2-Aminoethanesulfonic Acid in Compound Edaravone Injection

A Phase 1 interventional study of Compound Edaravone Injection and Edaravone Injection in Drug-drug Interaction, sponsored by Nanjing Yoko Biomedical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-22.

Sponsored by Nanjing Yoko Biomedical Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled May 2019, registered Dec 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

An experiment to evaluate the drug-drug interaction of formula edaravone and formula 2-aminoethanesulfonic acid in compound edaravone injection.

02

Conditions studied

  • Drug-drug Interaction

Keywords

  • Drug-drug Interaction
  • Edaravone
  • 2-Aminoethanesulfonic Acid
  • Compound Edaravone Injection
03

In context

Lead sponsor

Nanjing Yoko Biomedical Co., Ltd. is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 18-65 years old (including upper and lower limits);
  2. Weight ≥50 kg, (BMI) between 18-28 kg / m2 (including upper and lower limits);
  3. Understand and sign the voluntarily, and volunteer to participate in this research.

Exclusion criteria

Exclusion Criteria:

  1. A history of diseases of the heart, liver, lung, kidney, digestive tract, blood, or neuropsychiatric system judged by the investigator as ;
  2. A comprehensive physical examination, neurological examination, laboratory examination, examination, or cognitive assessment indicates that the subject has an abnormality that the researcher has determined to be clinically significant;
  3. Have taken any drug within two weeks before the study administration, and the researcher believes that this situation may affect the evaluation results of this study;
  4. There is a history of food or drug allergy or allergies that the researcher judges to be clinically significant;
  5. Those with positive results of serological examination (, anti-, anti-, TP-Ab);
  6. A history of alcohol or drug abuse that the investigator believes may affect the evaluation results of this study within one year before the study administration;
  7. Cannot quit smoking or drinking during the study period or the carbon monoxide breath test> 7 ppm during the screening period CO breath test, so if the subject's CO breath is> 7ppm, but the urine cotinine test is negative, it means that the CO breath test result may be false positive, the subject can be enrolled;
  8. As a subject who has participated in any drug clinical trial within 3 months before the first administration of the study;
  9. Those who donated blood or blood products ≥400 mL or 2 units within three months of the study;
  10. Do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or vigorous exercise, or other factors that affect drug absorption, distribution, metabolism, excretion, etc. during the 24 hours before and during the test;
  11. Pregnant or lactating women, or those who tested positive for serum HCG before the test administration, or those who were unable or unwilling to take researcher-approved during the study according to the researcher's instructions;
  12. Subjects with poor compliance or unable to comply with the relevant provisions of the research protocol due to personal reasons, the investigator judges that the subjects are not suitable to participate in this clinical study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Compound Edaravone

    30 mL (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg)

    Drug: Compound Edaravone Injection

  • Experimental
    Edaravone

    30 mL (containing edaravone 30 mg)

    Drug: Edaravone Injection

  • Experimental
    2-Aminoethanesulfonic Acid

    30 mL (containing 2-aminoethanesulfonic acid 600 mg)

    Drug: 2-Aminoethanesulfonic Acid Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid

    Time frame: 24 hours

  2. AUC0-t of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid

    Time frame: 24 hours

  3. AUC0-∞ of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid

    Time frame: 24 hours

07

Study locations

1 site
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing 100050, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in May 2019, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2019
First posted
Jan 6, 2020
StartActual
May 10, 2019
Primary completionActual
May 31, 2019
CompletionActual
May 31, 2019
Last update
Mar 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04218513
Lead sponsor
Nanjing Yoko Biomedical Co., Ltd.
Responsible party
Sponsor
First posted
Jan 6, 2020
Start date
May 10, 2019
Primary completion
May 31, 2019
Completion
May 31, 2019
Last update
Mar 22, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Edaravone · Taurine

Start the discussion